Overview Type 2 Diabetes Patients With Renal Impairment Status: Not yet recruiting Trial end date: 2020-10-01 Target enrollment: Participant gender: Summary The purpose of the study is to evaluate the effect of kidney function on pharmacokinetics and pharmacodynamics of DWP16001 following single and multiple oral doses in type 2 diabetes patients with normal kidney function and renal impairment. Phase: Phase 1 Details Lead Sponsor: Daewoong Pharmaceutical Co. LTD.